Medicago and GSK announce research collaboration agreement to develop COVID-19 vaccine
July 06, 2020
On July 7, 2020, GlaxoSmithKline (GSK) and Medicago announced that they had entered into a research collaboration agreement to develop and evaluate a COVID-19 candidate vaccine, combining Medicago’s recombinant Coronavirus Virus-Like Particles (CoVLP) with GSK’s pandemic adjuvant system.
Phase 1 of clinical testing commenced in July 2020. Subject to successful testing, Medicago and GSK plan to make a vaccine candidate available in the first half of 2021.
Medicago is a biopharmaceutical company headquartered in Quebec City focused on plant-based technologies and medical remedies.
McCarthy Tétrault advised Medicago with a team led by Philippe Leclerc that included Veronique Wattiez-Larose, Dominic Therien (Competition), and Lisa Melanson (Regulatory).